Claims
- 1. A method of treating neurologic hemorrhage comprising:
inserting a inflow catheter and an outflow catheter into a cerebrospinal pathway to create a flow pathway for irrigating the area of the hemorrhage; and irrigating via the flow pathway the area of the hemorrhage with a synthetic cerebrospinal fluid for a period of time effective to reduce an indication of the presence of blood in effluent from the outflow catheter.
- 2. The method of claim 1, wherein irrigating is maintained for at least, in aggregate, 6 hours.
- 3. The method of claim 1, wherein the flow rate is at least 5 mL/min.
- 4. The method of claim 1, wherein said synthetic cerebrospinal fluid contains an aqueous emulsion of a fluorocarbon.
- 5. The method of claim 1, wherein said fluorocarbon is bis-perfluorobutyl ethylene (F44E).
- 6. The method of claim 1, wherein the synthetic cerebrospinal fluid comprises an effective amount of a physiologically acceptable suspending or solubilizing agent for hydrophobic biomaterials.
- 7. The method of claim 6, wherein the suspending or solubilizing agent is phospholipid.
- 8. The method of claim 6, wherein the suspending or solubilizing agent is serum albumin.
- 9. The method of claim 1, further comprising:
administering in the synthetic cerebrospinal fluid an effective amount of a thrombolytic agent, an antioxidant, or a vasodilating agent.
- 10. The method of claim 1, further comprising:
after the period of time, adding to the synthetic cerebrospinal fluid an effective amount of a thrombolytic agent, an antioxidant, or a vasodilating agent and continuing the perfusion for a second period of time.
- 11. The method of claim 10, further comprising:
after the second period of time, continuing the perfusion with the synthetic cerebrospinal fluid lacking the added thrombolytic agent, antioxidant, or vasodilating agent.
- 12. The method of claim 1, further comprising:
monitoring the amount of subarachnoid blood in the cerebrospinal pathway, or in effluent from the irrigating flow; and ending irrigating flow when the monitored amount reduces below a predetermined value.
- 13. The method of claim 1, wherein the synthetic cerebrospinal fluid comprises:
- 14. The method of claim 13, wherein the synthetic cerebrospinal fluid comprises 5-20% w/v of an oxygen-carrying fluorocarbon compound.
- 15. The method of claim 13, wherein the synthetic cerebrospinal fluid comprises 10 to 30 mg/mL of albumin.
- 16. The method of claim 13, wherein the synthetic cerebrospinal fluid comprises a nutritional amount of lysine, alanine, serine, threonine, arginine, leucine, isoleucine, valine, phenylalanine, tyrosine, histidine, methionine and α-ketoglutaric acid.
- 17. The method of claim 1, further comprising,
surgically removing a subarachnoid clot.
- 18. The method of claim 1, wherein the synthetic cerebrospinal fluid is infused into the subarachnoid space of the brain, and drained from the spinal subarachnoid space.
- 19. The method of claim 1, wherein the irrigating is initiated prior to, or concurrently with, initiating an operation to repair an aneurysm.
- 20. The method of claim 17, wherein the synthetic cerebrospinal fluid is maintained at a temperature from 15° C. to 35° C. during the operation.
- 21. The method of claim 1, wherein the neurologic hemorrhage is IVH, ICH or SCH.
- 22. A synthetic cerebral spinal fluid comprising:
a physiologically acceptable mixture of salts; serum albumin in an amount effective to provide an oncotic pressure of one to seven torr; one or more of (a) a clot-dissolving effective amount of tPA or urokinase or (b) a free-radical formation inhibiting effective amount of ascorbic acid.
- 23. The synthetic cerebral spinal fluid of claim 22, wherein the serum albumin is human serum albumin.
- 24. The synthetic cerebral spinal fluid of claim 22, wherein the serum albumin is present in an amount effective to reduce swelling of neurologic tissue at flow rates through the cerebrospinal pathway in excess of 2 mL/min.
- 25. A method of reducing the occurrence of or ameliorating the severity of neurologic adhesion resulting from a surgery on cerebrospinal tissue or from an inflammation of cerebrospinal tissue comprising:
identifying a subject with a tissue at risk for forming a neurologic adhesion resulting from a surgery on cerebrospinal tissue or from an inflammation of cerebrospinal tissue; inserting a inflow catheter and an outflow catheter into a cerebrospinal pathway to create a flow pathway for irrigating the tissue; and irrigating via the flow pathway the tissue with a synthetic cerebrospinal fluid, wherein, in the case of surgery the synthetic cerebrospinal fluid does not have a respiration-supporting amount of oxygen, and wherein the inflammation of cerebrospinal tissue does not result from stroke.
- 26. The method of claim 25, wherein irrigating is maintained for at least, in aggregate, 6 hours.
- 27. The method of claim 25, wherein the flow rate is at least 5 mL/min.
- 28. The method of claim 25, wherein said synthetic cerebrospinal fluid contains an aqueous emulsion of a fluorocarbon.
- 29. The method of claim 25, wherein said fluorocarbon is bis-perfluorobutyl ethylene (F44E).
- 30. The method of claim 25, wherein the synthetic cerebrospinal fluid comprises an effective amount of a physiologically acceptable suspending or solubilizing agent for hydrophobic biomaterials.
- 31. The method of claim 30, wherein the suspending or solubilizing agent is phospholipid.
- 32. The method of claim 30, wherein the suspending or solubilizing agent is serum albumin.
- 33. The method of claim 25, further comprising:
administering in the synthetic cerebrospinal fluid an effective amount of a thrombolytic agent, an antioxidant, or a vasodilating agent.
- 34. The method of claim 25, wherein the synthetic cerebrospinal fluid comprises:
- 35. The method of claim 34, wherein the synthetic cerebrospinal fluid comprises 5-20% w/v of an oxygen-carrying fluorocarbon compound.
- 36. The method of claim 34, wherein the synthetic cerebrospinal fluid comprises 10 to 30 mg/mL of albumin.
- 37. The method of claim 34, wherein the synthetic cerebrospinal fluid comprises a nutritional amount of lysine, alanine, serine, threonine, arginine, leucine, isoleucine, valine, phenylalanine, tyrosine, histidine, methionine and α-ketoglutaric acid.
- 39. The method of claim 25, wherein the synthetic cerebrospinal fluid is infused into the subarachnoid space of the brain, and drained from the spinal subarachnoid space.
- 40. The method of claim 39, wherein the synthetic cerebrospinal fluid is maintained at a temperature from 15° C. to 35° C. during the operation.
Parent Case Info
[0001] This application claims the priority of U.S. Provisional Applications No. 60/316,235, filed Aug. 31, 2001 and No. 60/347,398, filed Jan. 10, 2002, both of which are incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60316235 |
Aug 2001 |
US |
|
60347398 |
Jan 2002 |
US |